Spots Global Cancer Trial Database for high grade serous ovarian cancer
Every month we try and update this database with for high grade serous ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| miRNAs in High Grade Serous Ovarian Cancer | NCT05146505 | High Grade Sero... | - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | ||
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | NCT05329545 | High Grade Sero... Fallopian Tube ... Primary Periton... | Upifitimab rils... Placebo | 18 Years - | Mersana Therapeutics | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | NCT06136884 | Triple Negative... High Grade Sero... Endometrial Can... | AO-252 | 18 Years - | A2A Pharmaceuticals Inc. | |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01883297 | Recurrent Platinum-resist... High Grade Sero... Fallopian Tube ... Primary Periton... | Re-stimulated t... Interleukin-2 Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| Expanded Access to Veliparib | NCT03123211 | Solid Tumors Wi... Triple Negative... High Grade Sero... Patients Requir... | Veliparib | - | AbbVie | |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | NCT05512208 | Endometrioid Ca... Mucinous Ovaria... High Grade Sero... Cervical Cancer Solid Tumor | Avutometinib (V... | 18 Years - 99 Years | University of Oklahoma | |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | NCT01853306 | Oncology BRCA Mutated High Grade Sero... BRCA Mutated Br... | Veliparib | 18 Years - 99 Years | AbbVie | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| miRNAs in High Grade Serous Ovarian Cancer | NCT05146505 | High Grade Sero... | - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | ||
| NUVOLA TRIAL Open-label Multicentre Study | NCT04261465 | High Grade Sero... | Olaparib Paclitaxel Carboplatin | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | NCT01853306 | Oncology BRCA Mutated High Grade Sero... BRCA Mutated Br... | Veliparib | 18 Years - 99 Years | AbbVie | |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | NCT03268382 | High-grade Sero... | APR-246 Pegylated Lipos... | 18 Years - | Aprea Therapeutics | |
| A Study of SGN-B6A in Advanced Solid Tumors | NCT04389632 | Carcinoma, Non-... Squamous Cell C... HER2 Negative B... Esophageal Squa... Esophageal Aden... Gastroesophagea... Ovarian Neoplas... Cutaneous Squam... Exocrine Pancre... Urinary Bladder... Uterine Cervica... Stomach Neoplas... | sigvotatug vedo... pembrolizumab cisplatin carboplatin | 18 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
